Vivos Therapeutics, Inc. (VVOS) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day, everyone, and welcome to the Vivos Therapeutics first quarter 2025 earnings call. At this time, participants are in a listen-only mode. A question and answer session will follow management's remarks. This conference call is being recorded and replayed. For today's call, we'll be available on the investor relations section of Vivos' website and will remain posted there for the next 30 days. I will now hand the call over to Brad Ammon. Chief Financial Officer, for introductions and the reading of the Safe Harbor Statement. Please go ahead. Thank you, John. Hello, everyone, and welcome to our conference call. A copy of our earnings press release is available on the Investor Relations section of our website at www.vivos.com. With us on today's call are Kirk Huntsman, Vivos Chairman and Chief Executive Officer, and myself, Vivos Chief Financial Officer. Today, we'll review the highlights and financial results for the first quarter 2025, as well as more recent developments and vivos plans for the rest of 2025, including developments in our marketing and distribution strategy pivot. Following these formal remarks, we will take questions. I would also like to remind everyone that today's call will contain certain forward-looking statements from our management made with Within the meaning of Section 27A of the Securities Act of 1933 as amended and Section 21E of the Securities and Exchange Act of 1934 as amended concerning future events, words such as aim, may, could, should, seek, projects, expects, intends, plans, believes, anticipates, hopes, estimates, goal, and variations of such words and similar expressions are intended to identify forward-looking statements. These statements involve significant known and unknown risks and are based upon a number of assumptio...